Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.
Quick Facts
What This Study Found
PRRT with somatostatin analogs shows disease control rates up to 80% in lung carcinoids, paragangliomas, and meningiomas, but only 177Lu-DOTATATE is approved (for GEP-NETs). Combination and alpha-emitter therapies are emerging.
Key Numbers
177Lu-DOTATATE approved for GEP-NETs; disease control up to 80% in lung carcinoids, paragangliomas, meningiomas; SST discovered 1972; 5 SSTR subtypes; combination and alpha-emitter therapies emerging
How They Did This
Narrative review of PRRT applications beyond GEP-NETs, covering efficacy data from retrospective studies, emerging combination strategies, and alpha-emitter therapy.
Why This Research Matters
Many cancers beyond gut neuroendocrine tumors express somatostatin receptors. Expanding PRRT approvals could help patients with limited treatment options.
What This Study Doesn't Tell Us
Narrative format. Most evidence is from small retrospective studies. No randomized trials for non-GEP-NET indications. Patient selection criteria not standardized across tumor types.
Trust & Context
- Original Title:
- Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.
- Published In:
- Journal of neuroendocrinology, 37(3), e70013 (2025)
- Authors:
- Santo, Giulia(2), di Santo, Gianpaolo(2), Cicone, Francesco, Virgolini, Irene
- Database ID:
- RPEP-13412
Evidence Hierarchy
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13412APA
Santo, Giulia; di Santo, Gianpaolo; Cicone, Francesco; Virgolini, Irene. (2025). Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.. Journal of neuroendocrinology, 37(3), e70013. https://doi.org/10.1111/jne.70013
MLA
Santo, Giulia, et al. "Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.." Journal of neuroendocrinology, 2025. https://doi.org/10.1111/jne.70013
RethinkPeptides
RethinkPeptides Research Database. "Peptide receptor radionuclide therapy with somatostatin anal..." RPEP-13412. Retrieved from https://rethinkpeptides.com/research/santo-2025-peptide-receptor-radionuclide-therapy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.